Sanofi Vostok JSC continues its expansion in the Orel Region with a full-cycle production of insulin as well as packaging of anti-cancer agents.
Russia starts the production of its first combined five-component vaccine to protect children from five common infections at once: tetanus, pertussis, diphtheria, poliomyelitis and H. influenza type b.
Denis Manturov, the Minister of Industry and Trade, and Andrey Klychkov, the Acting Governor of the Orel Region, signed an investment contract with the Sanofi Russian Company. According to this document, the investment in revamping the modern insulin production in the Orel Region will exceed 480 million rubles in 2017–2018, as reported by the regional government press service.
Sanofi-Aventis Vostok Plant in Orel Region intends to start its latest generation insulin deliveries to CIS and European countries in December 2016, according to the regional government.
"Trading with international partners is scheduled to start in December 2016. Deliveries of insulins from Orel to CIS and European countries including Germany will be a major milestone of improving Russia's export potential," the message runs.
An expertise center for the treatment of pancreatic diabetes and its complications will be established in the Oryol Region. The respective memorandum on understanding was signed today at the Saint Petersburg International Economic Forum (SPIEF) between the management of the region and Sanofi, the world’s leader in the healthcare industry, as the press office of the administration of the Oryol Region informed.
On May, 20 the production was launched at the Safoni Oryol site of the first Russian insulin validation series of the latest generation, characterized by fewer side effects. As the Head of the region told TASS earlier, the invested amount was over 1.5 bln rubles.
Today Sanofi-Aventis Vostok Orel (Sanofi Group of Companies) has launched the production of the first Russian insulin validation series of the latest generation, characterized by fewer side effects. The project costed 1.5 billion rubles.
Sanofi Russia JSC and Pharmstandard announce the signing of an agreement to set up local production of enoxaparinum natrium, a drug to treat cardiovascular diseases (Clexane).
In 2016–2018, Pharstandard UfaVita JSC will get a full cycle production line in place for the drug. Secondary packaging of the drug produced in France will be launched as early as 2015.
The Sanofi-Aventis East plant belongs to the French pharma corporation Sanofi and is located in the Oryol Region. In Q1 2016, it plans to start exporting insulin to the EU. The company has announced that the enterprise has undergone a European inspection and received a GMP certificate from the European Medicines Agency/EMA/.
The potential export volumes have not been determined yet, but the entire range of insulins produced by the plant is being considered for export.
The plant will continue producing insulin primarily for satisfying the needs of Russian patients. The volumes required for export to the EU will be manufactured using existing capacity and the only difference will be the language printed on the packaging, according to General Director of JSC Sanofi Russia Alexander Efremov.
Sanofi-Aventis East started producing insulin in the form of pen injectors in December 2010. In 2013, production reached full cycle. The production lines provide for production of up to 30 m units of dosage forms of insulin a year.
Sanofi operates in over 100 countries. The company was set up in 2004 through a merger between Sanofi-Synthelabo and Aventis. The company’s headquarters are located in Paris. Sanofi’s best-known medicines in Russia include Noshpa, Festal, Bronkhikum, Apidra, Maalox, Magne B6 and others. Sanofi’s vaccine division distributed vaccines against cholera, diphtheria, whooping cough, tetanus, tuberculosis, typhoid, hepatitis А and В, measles, polio, rabies, German measles, chicken pox and others on the Russian market.
Sanofi Pasteur, together with Nanolek, plans to start producing its own pentavalent combined vaccine Пентаксим® in Russia. It protects against five infections: diphtheria, tetanus, whooping cough, poliomyelitis and haemophilia infection type b and is given in the first two years of a child’s life. The vaccine was registered in Russia in 2008 and is widely used in paediatrics.
It is planned to produce the vaccine at Nanolek’s factory in the Kirov Region.
“The joint project with one of the world’s biggest vaccine manufacturers, Sanofi Pasteur, will be a major step in Nanolek’s development”, said Vladimir Khristenko, Nanolek’s President. “Our biopharmaceutical complex is an ideal platform for such a complex process as localisation of a combined vaccine. When operating at design capacity, Nanolek will be manufacturing up to 10 million doses of Пентаксим® a year.
French pharma major Sanofi (Euronext: SAN) plans to build a new plant in Russia, which is expected to be located in the St Petersburg region.
It is reported that the company held preliminary talks with the representatives of the St Petersburg government during the recent XIII International Investment Forum "Sochi-2014," which was organized in Sochi.
Details of the project, as well as potential production volumes of the plant, are not disclosed. The company already owns a factory for the production of insulin in Russia’s Orel.
France-based pharmaceutical company Sanofi-aventis has announced the launch of a new plant making insulin at Oryol, Russia.
Sanofi has produced insulin in Russia since 2010, when the firm acquired a controlling stake in an insulin production unit in Oryol. Over the following two years, the plant produced several validation series of insulin and fine-tuned its manufacturing processes.
In February 2013, the company was registered to run a full production cycle. Now, compact injection pens will undergo all stages of production - from assembly to final testing and shipment to the place of sale - at the new plant in Oryol.
Sanofi-Aventis Vostok is capable of producing up to 30 million insulin injection pens per year.
Company's website: https://www.sanofipasteur.com
T: +33 153774000
Contact: Mr Chris Viehbacher, General Director
Sanofi Pasteur, the vaccine subdivision of the Sanofi Group, is the biggest company in the world engaged exclusively in human vaccines.
Sanofi SA is a pharmaceutical firm. Backed by an R&D organisation, Sanofi operates in seven therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines.